New location offers more space for expansion and designed to inspire innovation of Lumicell technology through further employee collaboration
Newton, Mass., Feb. 22, 2019— Lumicell, Inc., an innovation leader in molecular imaging within healthcare focused in cancer, perfusion, wound care and infection, has expanded into a new headquarters location in Newton, Mass., just outside of Boston.
The new office space at One Newton Place, 275 Washington St., is over 20K sq. ft. in size and has been completely renovated to meet Lumicell’s needs for a contemporary workspace that is reflective of the collaboration and creativity required to develop their molecular imaging technology. This location is in an ideal area for Lumicell. Not only is it close to downtown Boston and Cambridge, where much of its research and development workforce hails from, but it also offers a more commercial setting for the business, with room for future expansions.
“This space represents a huge growth milestone for Lumicell. As we grow into more Oncology indications and future Healthcare projects, we now have an office environment that supports the expansion of our platform,” said Kelly Londy, CEO of Lumicell. “Every decision for this space was focused on efficiency, collaboration and technology that pushes engineering solutions to positively impact patients and clinicians. In fact, we have room for clinical trainings and education events with medical teams from hospitals and local universities who work collaboratively with our team.”
The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery. It features an investigational optical agent and a handheld device that enable cancer surgeons to see and remove cancer cells in real-time during operations. The Lumicell System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow.
About Lumicell, Inc.
Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The company’s Lumicell System has unprecedented ability to see and remove cancer cells remaining in the surgical cavity – beyond the margin of the specimen – and has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the Lumicell System in patients undergoing surgery for breast cancer, ovarian cancer, prostate cancer, brain cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include perfusion, wound care and infection, and surgeries for lung, and liver cancers. For more information, please visit www.lumicell.com.
